Non-Steroidal Injection Promises Relief From Low Back Pain

Skeptics of Intralink-Spine, Inc.’s Réjuve System treatment for lower back pain are turning into believers according to a news release from the company.

Data from a 12-month study of the safety and feasibility of the treatment indicates that the system continues to effectively eliminate or reduce low back pain and disability associated with degenerative disc disease.

“We continue to be very pleased with the patient outcomes,” said Tom Hedman, M.D., Ph.D., the inventor and Adjunct Associate Professor in the F. Joseph Halcomb, III, M.D. Department of Biomedical Engineering at the University of Kentucky.

“Twelve months after the Réjuve procedure, three of the four patients eligible for this follow-up assessment have no (zero) low back pain and no (zero) disability. And, the fourth patient has minimal pain and disability. These initial clinical results demonstrate a long-lasting, significant reduction or elimination of pain and disability, not just a slight reduction, and these benefits began within days of the initial procedure. We also have objective imaging data demonstrating the elimination of clinical instability.”

According to Lyle Hawkins, CEO of Intralink-Spine Inc.: “We understand that we need to evaluate this injectable device in a much larger group of patients in a multisite study, but we are very optimistic as we pursue that next milestone. We believe the Réjuve System which structurally reinforces the native intervertebral disc itself is going to be a better treatment option for many patients with low back pain. Réjuve has the procedural simplicity of an epidural steroid injection, but with potential long-term positive effects similar to a successful fusion.”

Intralink-Spine was formed to manufacture and exclusively sell the Réjuve injectable medical device to treat low back pain and related spinal diseases such as scoliosis and degenerative disc disease.